Truist Securities Maintains Buy on iRhythm Technologies, Lowers Price Target to $167

Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $185 to $167.

byBenzinga Newsdesk

October 17, 2022

1 minute read

Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $185 to $167.

Baird Maintains Outperform on Darling Ingredients, Raises Price Target to $109

By Benzinga Newsdesk

August 12, 8:31 AM

Baird analyst Ben Kallo maintains Darling Ingredients (NYSE:DAR) with a Outperform and raises the price target from $89 to $109.

DAR

CORRECTION: Benson Hill Q4 EPS Cont. Ops. $(0.17) Beats $(0.18) Estimate, Sales $99.18M Miss $101.42M Estimate

By Benzinga Newsdesk

March 13, 7:26 AM

Benson Hill, Inc. (NYSE: BHIL) reported quarterly losses from continuing operations of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent.

BHIL

Morgan Stanley Maintains Overweight on Constellation Energy, Raises Price Target to $102

By Benzinga Newsdesk

January 23, 9:00 AM

Morgan Stanley analyst David Arcaro maintains Constellation Energy (NASDAQ:CEG) with a Overweight and raises the price target from $99 to $102.

CEG

News

BD Selects “embecta” As Name Of New Company For Planned Spinoff Of Diabetes Care Business

By Benzinga Newsdesk

December 6, 7:51 AM

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that "embecta" [pronounced em-BECK-tah] will be the name of the independent, publicly-traded

BDX

Truist Securities Maintains Buy on iRhythm Technologies, Lowers Price Target to $167

Related Posts

Baird Maintains Outperform on Darling Ingredients, Raises Price Target to $109

CORRECTION: Benson Hill Q4 EPS Cont. Ops. $(0.17) Beats $(0.18) Estimate, Sales $99.18M Miss $101.42M Estimate

Morgan Stanley Maintains Overweight on Constellation Energy, Raises Price Target to $102

BD Selects “embecta” As Name Of New Company For Planned Spinoff Of Diabetes Care Business